TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes

Toll‐like receptor 2 (TLR2) expressed on antigen presenting cells evokes a series of critical cytokines, which favor the development of tumor‐specific cytotoxic T lymphocytes (CTLs). Therefore, TLR2 represents an attractive cancer immunotherapeutic target. Here, a synthetic library of 14 000 compoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Cen, Xiaohong, Zhu, Gengzhen, Yang, Junjie, Yang, Jianjun, Guo, Jiayin, Jin, Jiabing, Nandakumar, Kutty Selva, Yang, Wei, Yin, Hang, Liu, Shuwen, Cheng, Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523386/
https://www.ncbi.nlm.nih.gov/pubmed/31131189
http://dx.doi.org/10.1002/advs.201802042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523386/
https://www.ncbi.nlm.nih.gov/pubmed/31131189
http://dx.doi.org/10.1002/advs.201802042

Ejemplares similares